Neue Interpharma Boardmitglieder: «3 Fragen an» Christophe Griolet, General Manager Gilead Switzerland

Interpharma hat im Rahmen der jährlichen Generalversammlung fünf neue Boardmitglieder gewählt. In unserer Rubrik «3 Fragen an» werden wir die neuen Mitglieder über die kommenden Tage gerne kurz vorstellen.

Could you please give a short introduction of yourself and your current position at Gilead?

I am the General Manager of Gilead Switzerland and Member of the Board & the Executive Committee at Interpharma. I have been working 15+ years as a biotechnology & pharmaceutical professional at Global & Local Levels. Passionate about having an impact for Patients in areas of high unmet medical need, I have engaged deeply in disease areas such as Oncology, Hematology & Virology.

Which main focus do you want to get down to as your role as new board member at Interpharma?

Switzerland is a very dynamic & efficient environment. In order to keep improving early access to innovations, my engagement in the Board of Interpharma is motivated by the willingness to answer even more quickly the Patient Needs in a structured way involving all key stakeholders in healthcare.

How did Covid-19 influence your work in your current position and what are your expectations in 2021?

We have all been impacted by the Covid-19 Outbreak. At Gilead, as leader in Virology and with a treatment option for Covid-19, we have also been working closely with Authorities, HCPs & External Stakeholders very early in 2020. Many lessons have been learnt from this phase where efficient collaborations between the Pharmaceutical Industry & Local Authorities have enabled Early & Broad access for Patients in needs. Some powerful learning which could and should apply outside of a pandemics context too in 2021 and beyond.